Comparing the current results to its competitors, Cyclo Therapeutics Inc reported Revenue decrease in the 4 quarter 2024 year on year by -52.82 %, despite the revenue increase by the most of its competitors of 38.95 %, recorded in the same quarter.
Cyclo Therapeutics Inc 's Comment on Competition and Industry Peers
The company emphasizes its competitive advantage through established relationships with patient advocacy groups in the United States and Europe, as well as having a finished product currently used in human patients. It acknowledges increased competition in the distribution of small quantities of cyclodextrins but notes that competitors are either small operations or limited offerings from larger distributors lacking comparable focus, expertise, and price competitiveness. The company identifies a perceived barrier to entry in the cyclodextrin industry due to limited general experience and highlights its extensive business relationships with producers and consumers worldwide developed over more than 30 years. The company also references orphan drug exclusivity, which can prevent approval of competing products for seven years under certain conditions, while competitors may obtain approval for drugs with different active moieties or indications. Additionally, the company notes that the Affordable Care Act and comparative effectiveness research could affect the sales and coverage of its product candidate.
February 8, 2025
Unraveling Hope in Tiny Hearts: Cyclo Therapeutics Unveils Promising Phase 3 Data for NPC1 Treatment In a heartfelt juncture of science and compassion, Cyclo Therapeutics, Inc. (Nasdaq: CYTH) continues to blaze a trail in the field of rare disease treatment, with the most recent revelation from its TransportNPC Phase 3 open-label sub-study. Revealed at the prestigious 21st Annual World Orphan Drug Congress, these preliminary findings spell a beacon of hope for countless young lives marred by Niemann-Pick Disease Type C1 (NPC1).Niemann-Pick Disease Type C1, a lysosomal storage disorder, typically manifests as relentless neurological deterioration, leading to a cascade of challenges for the affected children a...
Bluebird Bio Inc's business model focuses on developing gene therapies for severe genetic diseases and cancer. They collaborate with academic and industry partners to leverage their gene editing and cell-based technologies for discovering potential treatments and advancing these therapies through clinical trials.
LogicBio Therapeutics Inc is a biotechnology company that focuses on developing and commercializing gene editing technology to treat rare genetic diseases.
Orchard Therapeutics Plc operates as a biotechnology company specializing in gene therapies for rare diseases. Their business model involves developing and commercializing potentially curative gene therapies to address the underlying cause of these diseases. They collaborate with academic and industry partners to advance their research and utilize their expertise to bring innovative therapies to patients in need.
Protalix Biotherapeutics Inc. operates under a business model focused on the development, production, and commercialization of recombinant therapeutic proteins using plant cell culture technology, aiming to address unmet medical needs and provide innovative treatment options to patients worldwide.
Sources:
Cyclo Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cyclo Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
